SEC Form 4 · accession 0001493152-26-039046
Dermata Therapeutics, Inc. · DRMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kyri K. Van Hoose
Officer — SVP, CFO
Period of report
Aug 16, 2026
Accepted (ET)
Aug 18, 2026 · 5:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001853816
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 16, 2026 | A | 102,040 | — | A | 232,463 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series E Warrant (Right to Buy)F2,F3 | $1.47 | Aug 16, 2026 | A | 102,040 | A | — | — | Common Stock | 102,040 | 102,040 | D |
| Series F Warrant (Right to Buy)F2,F4 | $1.47 | Aug 16, 2026 | A | 102,040 | A | — | — | Common Stock | 102,040 | 102,040 | D |
Explanation of responses
- F1The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock.
- F2The purchase price per share of common stock and accompanying warrants was $1.47.
- F3This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
- F4This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.